Jennifer Krimko Quoted in NJ.com Article About the Rezoning of a Historic Golf Course

The Old Orchard Country Club in Eatontown is moving closer to its transformation into an age-restricted housing development with open space and commercial uses on the highway. A recent ordinance amendment established new zoning regulations for the 94-year-old golf course, allowing up to 145 age-restricted, single-family homes with amenities off of Route 71 (Monmouth Road) and commercial development on Route 36. The firm, through Shareholder Jennifer S. Krimko represents the contract purchaser and future developer of Old Orchard. She addressed the Council at the hearing on the Ordinance and her sharing her statements on the zoning framework and the balance being struck between her client and the community is highlighted in this NJ.com article.

Jennifer is co-chair of Ansell.Law’s Land Use & Zoning Department. Our attorneys assist clients in navigating land development. They offer thorough advice on zoning due diligence and development prospects, managing the process from planning to compliance. From small renovations to large commercial projects, our attorneys are prepared to guide clients through the approval process. Please contact Jennifer for more information.

Joshua Bauchner Presenting During the New Jersey League of Municipalities Conference

Shareholder Joshua Bauchner will join a panel of experts presenting “The Municipal Cannabis Matrix Reloaded” at the New Jersey League of Municipalities Annual Conference in Atlantic City, November 14-16, 2023. The largest municipal gathering in the nation, this conference provides New Jersey’s local government officials and professionals with extensive learning opportunities, meaningful networking, and a comprehensive showcase of the latest product innovations.

The panel will provide a brief introduction to municipal cannabis before a discussion with city leaders exploring what is and is not working in their cities. Joshua will share insights on how to avoid municipal cannabis litigation. The panel will also address a checklist for governing bodies to consider when drafting or amending cannabis ordinances, police enforcement, smoke-free laws, and cannabis taxation for municipal tax assessors and CFOs. Learn more and register here.

Joshua leads Ansell.Law’s dedicated Controlled Substances & Regulatory Law Practice Group. Our attorneys understand the laws related to the production, sale, use, regulation, and legalization of controlled substances, including hemp, cannabis, and psychedelics. Controlled substance law remains a multifaceted and complex field with, at times, conflicting regulations from different governing bodies. We are prepared to assist in all aspects of this emerging field and are committed to helping our clients understand their rights and opportunities in this complex and evolving area of law. Please contact Joshua for additional information.

Joshua Bauchner Quoted in New Jersey Monitor Article

Shareholder Joshua Bauchner is quoted in a New Jersey Monitor article discussing the recent decision impacting New Jersey law enforcement officers’ rights to use cannabis when not on duty. The closely watched case of wrongful termination resulted in a win for police officers who want to use cannabis legally while off duty. The conflict between state and federal law makes this a complex and nuanced issue. Read the article.

Joshua leads Ansell.Law’s dedicated Controlled Substances & Regulatory Law Practice Group. Our attorneys understand the laws related to the production, sale, use, regulation, and legalization of controlled substances, including hemp, cannabis, and psychedelics. Controlled substance law remains a multifaceted and complex field with, at times, conflicting regulations from different governing bodies. We are prepared to assist in all aspects of this emerging field and are committed to helping our clients understand their rights and opportunities in this complex and evolving area of law. Please contact Joshua for additional information.

Controlled Substances & Regulatory Law August Update

In the rapidly evolving area of controlled substances law, our attorneys are at the forefront of recent developments and important issues affecting business owners in this exciting space. Read below to learn more.

New Lawsuit Challenges Unconstitutional Bureaucratic Overreach by New York Cannabis Regulators

A new lawsuit challenges unconstitutional overreach by NY cannabis regulators that has delayed or denied dispensary licenses for hundreds of qualified applicants. Read More.

New York’s Cannabis Control Board Approves New Regulations for Select Cannabinoid Products

To curtail the largely uncontrolled New York market of hemp-derived cannabinoids, state regulators recently approved new regulations. However, these regulations are having an immediate negative impact on thousands of small businesses. Read More.

Ansell Law’s New York Controlled Substances and Regulatory Law Capabilities

In addition to our strong foothold navigating New Jersey’s controlled substances industry, Ansell Law has a New York presence where we assist clients seeking a Conditional Adult-Use Retail Dispensary (CAURD) license. Read More.

New Cannabis License Categories Will Become Available in New Jersey

Beginning September 27, 2023, the New Jersey Cannabis Regulatory Committee (“CRC”) will open three new adult-use cannabis license categories- Wholesaler, Delivery, and Distribution- in the Garden State. Read More.

New Coalition Ups Pressure to Reschedule Cannabis From List of Controlled Substances

A new coalition of cannabis lawyers, researchers, activists, and businesses is ramping up pressure on the Biden Administration to either remove cannabis from the Controlled Substances Act’s list of controlled substances or reschedule it to a lower tier.  Read More.

In Major Advancement, FDA Issues First-Ever Draft Guidance on Clinical Trials for Psychedelic Drugs 

In a significant step that offers the promise of new medical treatments and advancements, the U.S. Food and Drug Administration issued its first-ever guidance for those wishing to study and test psychedelics for medicinal use. Read More.

Firm News

Joshua S. Bauchner and Kelsey M. Barber, two attorneys in our Controlled Substances and Regulatory Law Group, will present during the National Business Institute’s Marijuana Business Operations in New Jersey seminar on August 21, 2023. They will address critical human resources, labor, and employment issues affecting cannabis and marijuana businesses operating in New Jersey. Bauchner and Barber also will provide an ethics presentation exploring rules of professional conduct, the duty to pursue justice, attorney use of cannabis, and attorney ownership of cannabis businesses.

The full-day seminar will be offered live online on August 21, 2023, and available to view on demand. Learn more and register for this information-packed program presented by cannabis industry leaders.

Bauchner also contributed to the book “New Jersey Cannabis Regulation,” published by LexisNexis, which focuses on marijuana laws and regulations as interpreted by NJ courts. The book is available to order.

Ansell Law’s dedicated Controlled Substances & Regulatory Law Practice Group has an in-depth understanding of the laws related to the production, sale, use, regulation, and legalization of controlled substances, including hemp, cannabis, and psychedelics. Controlled substances law remains a multifaceted and complex field with, at times, conflicting regulations from different governing bodies. Our attorneys are prepared to assist in all aspects of this emerging field. We are committed to helping our clients understand their rights and the opportunities in this complex and evolving area of law. For additional information, please contact Joshua S. Bauchner or Kelsey M. Barber at (973) 247-9000.

New Lawsuit Challenges Unconstitutional Bureaucratic Overreach by New York Cannabis Regulators

Creation of Unauthorized CAURD Licensing Category Has Delayed or Denied Licenses for Hundreds of Qualified Applicants 

On August 2, 2023, a complaint was filed in the New York Supreme Court seeking to reverse the state’s regression from bureaucratic oversight to bureaucratic overreach regarding the regulation of its adult-use cannabis market. Filed on behalf of four service-disabled veterans who planned to pursue adult-use dispensary licenses, the suit asserts they were unfairly prejudiced by the actions of the state’s Office of Cannabis Management (OCM) and Cannabis Control Board (CCB) when those agencies unconstitutionally assumed the Legislature’s role by supplanting their own social and economic policies for those of New York’s elected officials.

The complaint illustrates a common and concerning issue that has arisen in several East Coast states that have legalized recreational marijuana in recent years. Specifically, the institution of regulatory schemes of dubious legality that have delayed the creation and implementation of well-regulated and equitable cannabis markets as set forth in the legislation authorizing those markets. These transgressions have led authorities to spend their time and resources engaged in artificial and harmful enforcement actions against individuals simply attempting to avail themselves of legalization’s intended opportunities and benefits.

CAURD License Scheme Unauthorized by Legislature

In this case, the plaintiffs are challenging the OCM’s and CCB’s creation of an entirely new licensing category called the Conditional Adult-Use Retail Dispensary (the “CAURD”) license. As outlined in the complaint, those bodies improperly limited eligibility for this special, yet legally impermissible, license category to only “justice-involved individuals” who own a profitable “qualifying business.” Subsequently, they opened the adult-use retail dispensary application period for only those individuals that qualified as CAURD applicants. This action indefinitely postponed the licensing of hundreds of additional dispensaries necessary to satisfy consumer demand, including licenses the plaintiffs intended to seek.

Accordingly, the plaintiffs are asking the court to enter an order declaring OCM’s CAURD license an unconstitutional licensing category that violates New York’s Marihuana Regulation and Taxation Act and contravenes New York’s separation of powers doctrine. They also ask the court to indefinitely enjoin OCM and CCB from awarding or further processing any more CAURD licenses and/or authorizing any more CAURD licensees to open adult-use retail dispensaries.

On August 7, 2023, the court entered a temporary restraining order prohibiting OCM and CCB from awarding or further processing any more CAURD licenses and/or conferring operational approval upon any more provisional or existing CAURD licensees. The litigation remains pending.

Ansell’s dedicated Controlled Substances & Regulatory Law Practice Group has an in-depth understanding of the laws related to the production, sale, use, regulation, and legalization of controlled substances, including hemp, cannabis, and psychedelics. Controlled substances law remains a multifaceted and complex field with, at times, conflicting regulations from different governing bodies. Our attorneys are prepared to assist in all aspects of this emerging field. They are committed to helping our clients understand their rights and opportunities in this complex and evolving area of law. For additional information, please contact Joshua S. Bauchner at (973) 247-9000 or jbauchner@ansell.law.



New York’s Cannabis Control Board Approves New Regulations for Select Cannabinoid Products

During a contentious assembly late last month, New York’s Cannabis Control Board (“CCB”) approved emergency regulations limiting the amount of THC allowed in products containing potentially intoxicating hemp-derived cannabinoids and banning some cannabinoids altogether.

Under the approved regulations, edible products must have a 15-to-1 ratio of CBD to THC and are limited to no more than 10 milligrams of THC per package and 1 milligram per serving. Retailers are also forbidden from selling products with more than 0.5 milligrams of THC to anyone younger than 21.

The new rules also ban Delta-8 THC, THC-A, and THC-O.

Until recently, companies selling hemp-derived cannabinoids could legally sell products containing the same amount of THC as those sold at licensed adult-use dispensaries.

New York regulators hope the move will ultimately curtail the largely uncontrolled market of hemp-derived cannabinoids, encompassing intoxicating delta-8 and delta-9 THC, alongside CBD. However, in the process, thousands of tax-paying small businesses throughout the State were suddenly rendered illegal, risking raids, seizures, fines, and closure. The ever-shifting regulatory landscape in the State continues to challenge operators seeking to engage in legal sales. More litigation against the OCM is sure to follow, further delaying the development of a lawful marketplace.

Our Controlled Substances and Regulatory Practice attorneys understand the complex laws related to the production, sale, use, regulation, and legalization of controlled substances, including hemp, cannabis, and psychedelics. A multifaceted area of the law with conflicting regulations from different governing bodies, we help our clients navigate all aspects of this emerging field. We are committed to helping our clients understand their rights and opportunities in this evolving area of law.

Ansell Law’s New York Controlled Substances and Regulatory Law Capabilities

As one of today’s most rapidly evolving industries, lawyers in the cannabis space must be experienced in licensing, operations, and employment issues, including drug testing. These issues vary by state, and navigating the legal landscape can be challenging. Led by shareholder Joshua S. Bauchner, the attorneys in our Controlled Substances and Regulatory Law Practice Group are well-versed in this emerging area of law. 

In addition to our strong foothold navigating New Jersey’s controlled substances industry, Ansell Law has a New York presence where we assist clients seeking a Conditional Adult-Use Retail Dispensary (CAURD) license. Different from medical dispensaries, CAURD license holders are the first retail dispensaries open for adult-use cannabis sales in the state of New York. Pursuing a CAURD license requires numerous considerations, including eligibility, the volume of applicants, state and federal legal issues, and necessary documentation. 

Our attorneys actively monitor industry developments to best facilitate positive outcomes for clients in the cannabis or controlled substances industries. For those seeking to do business in New York or New Jersey, contact Josh with any questions about this emerging area of law.

New Cannabis License Categories Will Become Available in New Jersey

Beginning September 27, 2023, the New Jersey Cannabis Regulatory Committee (“CRC”) will open three new adult-use cannabis license categories- Wholesaler, Delivery, and Distribution- in the Garden State. Ansell Law remains prepared to assist clients seeking to secure one of these new license types as opportunities in this exciting industry develop.

  • Wholesale-Class Three License: A marijuana wholesaler license, also called a Class 3 license in New Jersey, allows the holder to purchase or obtain, store, sell or transfer, and transport marijuana products for resale or to other cannabis wholesalers or retailers.
  • Distribution-Class Four License: A cannabis distributor, also a Class 4 license, enables distributors to transport marijuana items in bulk intrastate from one licensed marijuana establishment to another and store the marijuana or marijuana products briefly, if necessary, to fulfill their duties in transporting the goods.
  • Delivery- Class Six License: A delivery license or Class 6 license offer a cost-effective gateway for many aspiring entrepreneurs to enter the cannabis industry. Similar to food delivery services such as GrubHub or DoorDash, these licenses empower businesses to Transport a consumer’s purchases of recreational use cannabis and related supplies from the retailer to that consumer from cannabis retailers.

With 9 million residents, millions of annual visitors, a higher-than-average national income, and an estimated adult-use market that is projected to generate $850 million-$950 million in annual retail sales by 2024, the CRC’s rollout of Class Three, Four, and Six licenses represents a significant advance in the already lucrative and flourishing State cannabis market.

Starting September 27, social equity applicants—including those with previous marijuana-related convictions and individuals from economically disadvantaged regions seeking wholesale, distributor, and delivery licenses get priority for three months. Then for the next three months, diversely owned cannabis businesses—owned by women, minorities, or disabled veterans—receive priority.

Our Controlled Substances and Regulatory Practice attorneys understand the complex laws related to the production, sale, use, regulation, and legalization of controlled substances, including hemp, cannabis, and psychedelics. A multifaceted area of the law with conflicting regulations from different governing bodies, we help our clients navigate all aspects of this emerging field. We are committed to helping our clients understand their rights and opportunities in this evolving area of law.

New Coalition Ups the Pressure on Biden Administration to Finally Deschedule – or at Least Reschedule — Cannabis From List of Controlled Substances

By Joshua S. Bauchner

With most Americans now living in states that have legalized adult-use cannabis, the federal foot-dragging on the removal of cannabis from the list of Schedule I controlled substances is more unsupportable, unsustainable, and illogical than ever. This classification means cannabis is considered to have no accepted medical use, a high potential for abuse, and no accepted safety standards even under medical supervision – all criteria which are unsupported and contradicted by the evidence. But even though grouping marijuana with such drugs as cocaine, heroin, and methamphetamines under the federal Controlled Substances Act (CSA) never made much scientific or societal sense, efforts to correct this long-standing error were consistently met with opposition, inertia, and inaction.

Now, a new coalition of cannabis lawyers, researchers, activists, and businesses is ramping up pressure on the Biden administration to finally address the issue and either remove cannabis from the CSA’s list of controlled substances or reschedule it to a lower tier. On June 26, 2023, the recently formed Coalition for Cannabis Scheduling Reform submitted a comprehensive report to the administration that methodically and persuasively makes a case for the multidimensional benefits of descheduling or rescheduling.

The report comes at a cautiously optimistic time for descheduling advocates, as President Biden has expressed more openness to changing marijuana’s classification than any of his predecessors. But he does not have the power to do so with the stroke of a pen. Accordingly, in October 2022, the president asked the Department of Justice (DOJ) and the Department of Health and Human Services (HHS) to initiate an administrative process to review the propriety of marijuana’s classification under the CSA. 

Before initiating proceedings to schedule, reschedule, or deschedule a drug, the U.S. Drug Enforcement Administration (DEA) must gather necessary data, request a scientific and medical evaluation from HHS, and request a scheduling recommendation from HHS. This process also includes a review by the Food and Drug Administration (FDA) as to appropriately regulating cannabis. 

In its report, the CCSR said that “Descheduling is the optimal outcome and the one that would mark the greatest improvement over the status quo possible without congressional intervention,” It argued that “Descheduling marijuana is sound public policy, supported by both the science and the law, as recent and compelling medical and public health data clearly demonstrate that marijuana simply does not belong in the CSA at all.”

However, the authors continued, if the FDA “determines that it cannot find its way to recommending marijuana descheduling, the Agency should instead recommend rescheduling to schedule III, IV, or V.”

HHS Secretary Xavier Becerra recently said that he hopes his agency will be able to present the president with a scheduling decision by the end of this year. While most observers believe that the FDA is more likely to reschedule cannabis than deschedule it entirely, any progress on the federal front would be better than the current state of affairs.

Ansell’s dedicated Controlled Substances & Regulatory Law Practice Group has an in-depth understanding of the laws related to the production, sale, use, regulation, and legalization of controlled substances, including hemp, cannabis, and psychedelics. Controlled substances law remains a multifaceted and complex field with, at times, conflicting regulations from different governing bodies. Our attorneys are prepared to assist in all aspects of this emerging field. They are committed to helping our clients understand their rights and the opportunities in this complex and evolving area of law. For additional information, please contact Joshua S. Bauchner at (973) 247-9000 or jb@ansellgrimm.com.

SEC Approves Sweeping FINRA Rule Changes That Will Make Expungement More Difficult for Broker-Dealers and Associated Persons

By Seth M. Rosenstein

It is the rare FINRA-registered professional who does not face a customer complaint at some point in their career, and it is rarer still to find one who would not prefer to have customer dispute information expunged from the Central Registration Depository (“CRD”). But on April 12, 2023, the SEC approved changes to the FINRA rules regarding expungements and expungement hearings that will significantly alter how and when negative marks on professionals’ records are removed from the CRD and BrokerCheck.

The substantive and procedural changes were largely due to pressure put on FINRA by customer advocates and state securities regulators to make it more difficult to obtain an expungement. A 2021 PIABA study, for example, revealed that FINRA arbitrators approved 90% of the expungement requests they received.

Concerns About Straight-in-Requests in Particular

While some updates relate to all requests for expungement of customer dispute information, others only apply to each of the two types of hearings through which expungements can be obtained. This includes specific procedural changes to “straight-in-request” arbitration hearings, which are commenced by an associated person separate from a customer-initiated arbitration (as opposed to “on-behalf-of-requests” that are filed at the conclusion of an investment-related customer-initiated arbitration).

FINRA was particularly concerned about issues with straight-in-request arbitration proceedings, which often involve complaints brought and resolved many years before the expungement request. As FINRA expressed in an April 2022 discussion paper, the rule changes sought to address four shortcomings it identified with such hearings:

  • The unavailability of documents or information relating to disputes that occurred years prior. FINRA noted that two-thirds of straight-in-requests filed between 2016-2021 were filed more than six years after the customer dispute was initially reported.
  • The lack of customer participation in straight-in-requests leading to only one side presenting evidence and testimony.
  • The firm named in a straight-in request may have no relevant documents pertaining to the customer dispute because the event occurred while the associated person was employed at a different firm.
  • “Arbitrator shopping” by associated persons who make repeated attempts to seek expungement of the same customer dispute.

Changes That Apply to All Expungement Arbitration Hearings

These updates apply to both straight-in-request (FINRA Rule 13805) and on-behalf-of-request (FINRA Rule 12805) expungement hearings:

  • Arbitration panels can only issue expungement relief if they unanimously find that:
    • the claim or allegation is factually impossible or clearly erroneous;
    • the associated person was not involved in the alleged conduct; or
    • the claim or allegation is false.
  • FINRA must notify state securities regulators of all expungement requests.
  • The associated person requesting expungement must appear at the hearing in person or by video conference.
  • FINRA must notify involved customers of the time, date, and place of any prehearing conferences and the expungement hearing, advise them that they may attend and participate in those proceedings, and provide access to all relevant documents filed in the matter.
  • Panels are authorized to request any evidence the panel members consider relevant from the broker-dealer firm or associated person.
  • Panels must explain their rationale in sufficient detail when granting expungement relief.
  • Associated persons may not request expungement if a panel previously considered the merits of, or a court previously denied, an expungement request involving the same customer dispute information.
  • An associated person who withdraws an expungement request cannot subsequently re-file the request.

Changes to Straight-In-Request Hearings Under FINRA Rule 13805

To address the concerns above about straight-in-request hearings, FINRA made the following rule changes for such proceedings:

  • FINRA will not consider expungement requests filed:
    • more than three years after the date the customer complaint was initially reported in the CRD; or
    • more than two years after the customer-initiated arbitration or litigation involving the customer dispute information is fully adjudicated.
  • Straight-in requests must be filed against the broker-dealer firm at which the associated person was associated at the time of the events underlying the dispute.
  • An authorized representative of a state securities regulator may attend and participate as a non-party in the proceedings to the same extent that a customer could.
  • All straight-in requests must be decided by a three-person panel composed of randomly selected arbitrators pulled from a roster of experienced public arbitrators with enhanced expungement training and no significant ties to the industry. Parties cannot:
    • agree to fewer than three arbitrators;
    • strike any of the selected arbitrators;
    • agree to an arbitrator’s removal; or
    • agree to use arbitrators they pre-select.

Conclusion

The SEC’s 158-page notice approving FINRAs proposed rule changes contains several other modifications that impact an associated person’s ability to obtain an expungement, and FINRA has not yet announced an effective date for these changes. We will provide an update when they do. But given that the additional modifications generally make expungement more challenging, industry professionals contemplating an expungement request may wish to proceed sooner than later.

If you have questions about these updates, please contact Seth Rosenstein at Ansell, Grimm & Aaron.